- Home
- HXHX vs PULM Comparison
HXHX vs PULM Comparison
Compare HXHX & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HXHX | PULM |
|---|---|---|
| Founded | 2003 | 2003 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8M | 6.2M |
| IPO Year | 2022 | 2013 |
Fundamental Metrics
Financial Performance| Metric | HXHX | PULM |
|---|---|---|
| Price | $0.41 | $1.60 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 295.2K | 43.5K |
| Earning Date | 05-20-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 46.18 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,910,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1.96 | ★ N/A |
| Revenue Growth | N/A | ★ 5069.93 |
| 52 Week Low | $0.32 | $1.16 |
| 52 Week High | $1.67 | $5.50 |
Technical Indicators
Market Signals| Indicator | HXHX | PULM |
|---|---|---|
| Relative Strength Index (RSI) | 42.61 | 52.52 |
| Support Level | $0.35 | $1.44 |
| Resistance Level | $0.56 | $1.82 |
| Average True Range (ATR) | 0.05 | 0.10 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 16.09 | 49.23 |
Price Performance
Historical ComparisonAbout HXHX Haoxin Holdings Limited Class A Ordinary Shares
Haoxin Holdings Ltd is a China-based logistics company engaged in temperature-controlled transportation and urban delivery services. The company provides cold chain logistics, freight forwarding, and related transportation services for goods, including new energy materials, electronic products, pharmaceuticals, meat, fruits, and vegetables. Its principal revenue streams are temperature-controlled truckload services and urban delivery services.
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).